Mutlu Hatice, Ekinci Zelal
Yuksekova Government Hospital, Hakkari, Turkey.
ISRN Pediatr. 2012;2012:317280. doi: 10.5402/2012/317280. Epub 2012 Jul 1.
Objectives. The aim of this randomized controlled prospective study is to evaluate the efficacy of cranberry capsules for prevention of UTI in children with neurogenic bladder caused by myelomeningocele. Patients and Methods. To be eligible for this study, patients had to be diagnosed as neurogenic bladder caused by myelomeningocele, evaluated urodynamically, followed up with clean intermittent catheterization and anticholinergic drugs. Intervention. Six months of treatment with placebo; after a week of wash-out period treatment of cranberry extract tablets (1 capsule/day) for an additional 6 months. Randomization was performed sequentially. Patients and care givers were blinded to drug assignment. Main outcome measure was infection rate. Group comparisons were performed with Wilcoxon test. Results. The study population included 20 (F/M: 13/7) patients with neurogenic bladder with the mean age of 7.25 ± 3.49 (4, 18) years. The median UTI rate was 0.5/year during placebo usage whereas 0/year during cranberry capsule usage. Decrease in infection rate was significant with cranberry capsule usage (P = 0.012). Decrease in the percentage of the pyuria was also recorded as significant (P = 0.000). Any adverse events or side effects were not recorded. Conclusion. We concluded that cranberry capsules could be an encouraging option for the prevention of recurrent UTI in children with neurogenic bladder caused by myelomeningocele.
目的。本随机对照前瞻性研究旨在评估蔓越莓胶囊对脊髓脊膜膨出所致神经源性膀胱患儿预防尿路感染的疗效。
患者与方法。符合本研究条件的患者必须被诊断为脊髓脊膜膨出所致神经源性膀胱,接受尿动力学评估,采用清洁间歇性导尿和抗胆碱能药物进行随访。
干预措施。给予安慰剂治疗6个月;在为期一周的洗脱期后,给予蔓越莓提取物片(每日1粒)治疗6个月。随机分组按顺序进行。患者及其护理人员对药物分配情况不知情。主要结局指标为感染率。采用Wilcoxon检验进行组间比较。
结果。研究人群包括20例(女性/男性:13/7)神经源性膀胱患者,平均年龄为7.25±3.49(4,18)岁。使用安慰剂期间尿路感染率中位数为每年0.5次,而使用蔓越莓胶囊期间为每年0次。使用蔓越莓胶囊后感染率显著降低(P=0.012)。脓尿百分比的降低也被记录为显著(P=0.000)。未记录到任何不良事件或副作用。
结论。我们得出结论,蔓越莓胶囊可能是预防脊髓脊膜膨出所致神经源性膀胱患儿复发性尿路感染的一个令人鼓舞的选择。